These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 34121700)
1. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer. Turker S; Cilbir E; Guven DC; Karacin C; Yalcin S J Cancer Res Ther; 2021; 17(2):510-515. PubMed ID: 34121700 [TBL] [Abstract][Full Text] [Related]
2. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer? Dogan M; Algin E; Guven ZT; Baykara M; Kos TF; Bal O; Zengin N Curr Med Res Opin; 2018 May; 34(5):857-863. PubMed ID: 29161926 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy. Kitsugi K; Kawata K; Noritake H; Chida T; Ohta K; Ito J; Takatori S; Yamashita M; Hanaoka T; Umemura M; Matsumoto M; Morita Y; Takeda M; Furuhashi S; Kitajima R; Muraki R; Ida S; Matsumoto A; Suda T Ann Med; 2024 Dec; 56(1):2398725. PubMed ID: 39221763 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer. Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090 [TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores. Hwang I; Kang J; Ip HNN; Jeong JH; Kim KP; Chang HM; Yoo C; Ryoo BY Invest New Drugs; 2019 Jun; 37(3):584-590. PubMed ID: 30324344 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer. Cetin S; Dede I J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169 [TBL] [Abstract][Full Text] [Related]
8. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer. Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900 [TBL] [Abstract][Full Text] [Related]
9. Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. Formica V; Morelli C; Ferroni P; Nardecchia A; Tesauro M; Pellicori S; Cereda V; Russo A; Riondino S; Guadagni F; Roselli M Cancer Biomark; 2016 Sep; 17(3):335-345. PubMed ID: 27434293 [TBL] [Abstract][Full Text] [Related]
10. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. Chawla A; Huang TL; Ibrahim AM; Hardacre JM; Siegel C; Ammori JB HPB (Oxford); 2018 May; 20(5):398-404. PubMed ID: 29221789 [TBL] [Abstract][Full Text] [Related]
11. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. Alagappan M; Pollom EL; von Eyben R; Kozak MM; Aggarwal S; Poultsides GA; Koong AC; Chang DT Am J Clin Oncol; 2018 Mar; 41(3):242-247. PubMed ID: 26757436 [TBL] [Abstract][Full Text] [Related]
12. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pancreatic ductal adenocarcinoma. Pointer DT; Roife D; Powers BD; Murimwa G; Elessawy S; Thompson ZJ; Schell MJ; Hodul PJ; Pimiento JM; Fleming JB; Malafa MP BMC Cancer; 2020 Aug; 20(1):750. PubMed ID: 32782024 [TBL] [Abstract][Full Text] [Related]
13. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412 [TBL] [Abstract][Full Text] [Related]
14. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer. Tingle SJ; Severs GR; Goodfellow M; Moir JA; White SA J Surg Oncol; 2018 Sep; 118(4):680-686. PubMed ID: 30196571 [TBL] [Abstract][Full Text] [Related]
15. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Geng Y; Qi Q; Sun M; Chen H; Wang P; Chen Z Eur J Surg Oncol; 2015 Nov; 41(11):1508-14. PubMed ID: 26343824 [TBL] [Abstract][Full Text] [Related]
16. The Neutrophil/Lymphocyte Ratio at Diagnosis Is Significantly Associated with Survival in Metastatic Pancreatic Cancer Patients. Piciucchi M; Stigliano S; Archibugi L; Zerboni G; Signoretti M; Barucca V; Valente R; Fave GD; Capurso G Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28353661 [TBL] [Abstract][Full Text] [Related]
17. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma. Chen Y; Yan H; Wang Y; Shi Y; Dai G Sci Rep; 2017 Apr; 7(1):753. PubMed ID: 28392554 [TBL] [Abstract][Full Text] [Related]
18. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients. Song A; Eo W; Lee S World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648 [TBL] [Abstract][Full Text] [Related]
19. Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer. Iwai N; Okuda T; Sakagami J; Harada T; Ohara T; Taniguchi M; Sakai H; Oka K; Hara T; Tsuji T; Komaki T; Kagawa K; Yasuda H; Naito Y; Itoh Y Sci Rep; 2020 Oct; 10(1):18758. PubMed ID: 33127996 [TBL] [Abstract][Full Text] [Related]
20. The Effect of Inflammatory Markers on Survival in Advanced Biliary Tract Carcinoma Treated with Gemcitabine/Oxaliplatin Regimen. Buyuksimsek M; Kidi MM; Ogul A; Mirili C; Paydas S J Gastrointest Cancer; 2021 Mar; 52(1):249-255. PubMed ID: 32185743 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]